- Home
- KYTX vs TLSA Comparison
KYTX vs TLSA Comparison
Compare KYTX & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYTX
- TLSA
- Stock Information
- Founded
- KYTX 2018
- TLSA 2013
- Country
- KYTX United States
- TLSA United Kingdom
- Employees
- KYTX N/A
- TLSA N/A
- Industry
- KYTX
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- KYTX
- TLSA Health Care
- Exchange
- KYTX NYSE
- TLSA Nasdaq
- Market Cap
- KYTX 92.1M
- TLSA 87.8M
- IPO Year
- KYTX 2024
- TLSA 2000
- Fundamental
- Price
- KYTX $2.11
- TLSA $1.57
- Analyst Decision
- KYTX Buy
- TLSA
- Analyst Count
- KYTX 5
- TLSA 0
- Target Price
- KYTX $18.80
- TLSA N/A
- AVG Volume (30 Days)
- KYTX 205.0K
- TLSA 468.1K
- Earning Date
- KYTX 05-16-2025
- TLSA 05-20-2025
- Dividend Yield
- KYTX N/A
- TLSA N/A
- EPS Growth
- KYTX N/A
- TLSA N/A
- EPS
- KYTX N/A
- TLSA N/A
- Revenue
- KYTX N/A
- TLSA N/A
- Revenue This Year
- KYTX N/A
- TLSA N/A
- Revenue Next Year
- KYTX N/A
- TLSA N/A
- P/E Ratio
- KYTX N/A
- TLSA N/A
- Revenue Growth
- KYTX N/A
- TLSA N/A
- 52 Week Low
- KYTX $1.78
- TLSA $0.54
- 52 Week High
- KYTX $17.55
- TLSA $1.91
- Technical
- Relative Strength Index (RSI)
- KYTX 48.82
- TLSA 64.57
- Support Level
- KYTX $1.92
- TLSA $1.49
- Resistance Level
- KYTX $2.38
- TLSA $1.78
- Average True Range (ATR)
- KYTX 0.17
- TLSA 0.18
- MACD
- KYTX 0.02
- TLSA 0.04
- Stochastic Oscillator
- KYTX 41.30
- TLSA 71.23
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.